相关实验视频

Updated: Jan 9, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

非典型慢性髓性白血病:从诊断到分子特征和治疗选择

Alessandra Iurlo¹, Daniele Cattaneo^1,2, Umberto Gianelli^3,4

¹Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.

|December 11, 2025

概括

非典型慢性髓性白血病 (aCML),现在被称为MDS/MPN与中性恋,是一种罕见的疾病,预后不佳. 目前的治疗方法缺乏疾病修饰,强调需要更好的风险分层和向治疗.

科学领域:

血液学血液学血液学
在瘤学瘤学.
遗传学遗传学是一个

背景情况:

异型慢性髓性白血病 (aCML) 是一种罕见的骨髓显样/骨髓扩散性瘤 (MDS/MPN) 重叠疾病.
它的特征是中性细胞细胞瘤,不成熟的髓状细胞,肝炎,以及高风险的白血病转变.
2022年世界卫生组织 (WHO) 的分类将aCML重新命名为"中性恋的MDS/MPN".

研究的目的:

审查诊断标准,遗传景观和aCML (中性恋的MDS/MPN) 的管理.
突出缺乏有效的风险分层和疾病修饰疗法.
讨论潜在的治疗点和全原干细胞移植的作用.

主要方法:

检查诊断标准,包括白细胞症,不成熟的髓状细胞和特定突变 (例如SETBP1,ASXL1).
对细胞遗传异常和复发性体质突变 (ASXL1,SETBP1,SRSF2,TET2,EZH2等) 的分析. ) 的情况.
评估当前的治疗方法 (基尿素,干扰素,低甲基化剂,JAK抑制剂) 和它们的局限性.

主要成果:

诊断标准包括特定的血细胞计数,骨髓检测结果,以及排除其他骨髓瘤.
在ASXL1,SETBP1和其他基因的反复突变是常见的,有助于疾病的复杂性.
目前没有一种治疗方法能够改变疾病;全源造血干细胞移植是唯一潜在的治愈选择.

结论:

中性友好症的MDS/MPN需要改进风险分层和新的治疗策略.
识别可操作的突变 (CSF3R,NRAS/KRAS,KIT) 为有针对性的药物开发提供了希望.
在符合条件的患者中,应考虑异构干细胞移植.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...